drugset / Trial / NCT07171619
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
Phase 1
Completed
24 enrolled
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Non-randomizedCrossoverOpen-labelTreatment
Summary
This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants
Timeline
- Start
- 2025-08-21
- Primary completion
- 2025-11-10
- Completion
- 2025-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Famotidine | Other / unclassified | 40 mg | Oral |
| Comparator | Nirogacestat | Small molecule | 150 mg | Oral |
| Comparator | Rabeprazole | Small molecule | 20 mg | Oral |
Indications
No indication recorded.